RPG Life Sciences Ltd

About

RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in the domestic and international market.[1]
The company is a part of RPG group which is a diversified conglomerate with interests in areas of infrastructure, tyres, information technology, pharmaceuticals, energy and plantations.[2] The group is headed by Harsh Goenka.[3]

Key Points

Domestic Formulations Segment (~62% of revenues)[1]
The company develops, manufactures and markets branded formulations in India & Nepal.[1] Its product portfolio includes various products which are sold under its key brands i.e. Azaron, Mofetyl, Lomitil, Arpimune, Imunotac, Serenace, etc. It launched 7 new products during FY21.
It has presence in various therapeutic segments such as nephrology, rheumatology, Oncology, Orthopaedics, Gastroenterology, and others.[2]

See full details
  • Market Cap 1,107 Cr.
  • Current Price 670
  • High / Low 752 / 339
  • Stock P/E 24.9
  • Book Value 131
  • Dividend Yield 1.08 %
  • ROCE 27.2 %
  • ROE 20.4 %
  • Face Value 8.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 28.10% CAGR over last 5 years

Cons

  • The company has delivered a poor sales growth of 6.86% over past five years.
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
90 91 69 94 98 94 89 92 97 108 93 108
83 79 62 79 82 79 76 75 78 86 80 85
Operating Profit 8 12 7 15 16 15 12 17 19 21 13 23
OPM % 9% 13% 10% 16% 17% 16% 14% 18% 20% 20% 14% 21%
Other Income 0 0 0 0 0 0 -5 0 0 0 0 0
Interest 1 1 1 1 0 0 0 0 0 0 0 0
Depreciation 4 4 4 4 4 4 4 4 4 4 4 4
Profit before tax 3 7 2 11 12 10 3 13 15 17 9 19
Tax % 30% 27% 27% 23% 19% 24% 5% 29% 24% 25% 23% 30%
Net Profit 2 5 2 8 10 8 3 9 11 13 7 14
EPS in Rs 1.31 3.19 0.93 5.05 5.91 4.78 1.80 5.48 6.74 7.78 4.18 8.21

Profit & Loss

Figures in Rs. Crores

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 TTM
159 187 193 222 236 242 279 294 344 330 376 389 406
130 154 175 206 224 228 256 274 306 296 315 318 330
Operating Profit 28 32 18 16 12 14 23 20 38 34 60 71 76
OPM % 18% 17% 9% 7% 5% 6% 8% 7% 11% 10% 16% 18% 19%
Other Income 4 1 1 2 66 1 1 18 1 1 -5 1 1
Interest 8 6 7 7 3 3 2 4 5 5 3 2 1
Depreciation 9 10 10 10 11 11 10 11 14 15 16 16 16
Profit before tax 15 17 2 1 65 1 12 23 20 15 36 54 60
Tax % 26% 27% 51% -717% 18% 0% 0% 10% 34% 28% 20% 25%
Net Profit 11 13 1 4 53 1 12 21 13 11 29 40 45
EPS in Rs 7.16 7.69 0.51 2.67 32.29 0.60 7.03 12.70 8.13 6.54 17.54 24.19 26.91
Dividend Payout % 20% 21% 156% 45% 6% 132% 23% 22% 30% 37% 23% 0%
Compounded Sales Growth
10 Years:8%
5 Years:7%
3 Years:4%
TTM:9%
Compounded Profit Growth
10 Years:12%
5 Years:28%
3 Years:44%
TTM:31%
Stock Price CAGR
10 Years:24%
5 Years:6%
3 Years:40%
1 Year:81%
Return on Equity
10 Years:10%
5 Years:14%
3 Years:16%
Last Year:20%

Balance Sheet

Figures in Rs. Crores

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
12 13 13 13 13 13 13 13 13 13 13 13
Reserves 52 62 61 63 113 112 120 134 142 147 163 203
Borrowings 49 53 54 63 15 33 23 45 54 36 12 2
54 62 54 67 56 39 49 55 82 54 78 85
Total Liabilities 167 189 183 206 196 197 205 247 291 251 267 303
108 112 109 103 106 105 109 137 131 128 123 113
CWIP 3 0 1 1 1 1 2 2 9 17 10 12
Investments 0 0 0 0 0 0 0 0 0 0 0 0
56 77 73 102 89 92 94 108 152 106 134 178
Total Assets 167 189 183 206 196 197 205 247 291 251 267 303

Cash Flows

Figures in Rs. Crores

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
21 14 16 12 -6 -2 33 7 15 46 50 58
-4 -13 -8 -12 59 -10 -15 -30 -16 -19 -11 -8
-16 -2 -8 -0 -54 12 -18 23 0 -26 -39 -10
Net Cash Flow 1 -0 0 0 0 -0 -0 1 -1 0 0 40

Ratios

Figures in Rs. Crores

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Debtor Days 72 75 57 81 56 61 48 49 72 43 62 54
Inventory Days 117 193 190 140 180 149 156 163 171 136 133 162
Days Payable 294 293 161 226 176 109 135 102 165 83 127 132
Cash Conversion Cycle -105 -24 86 -5 60 101 70 110 78 96 68 84
Working Capital Days 15 49 57 65 52 77 55 56 69 54 51 53
ROCE % 20% 20% 7% 6% 2% 2% 9% 10% 13% 10% 23% 27%

Shareholding Pattern

Numbers in percentages

Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
69.22 70.27 70.99 72.07 72.07 72.07 72.07 72.07 72.07 72.07 72.07 72.07
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00
0.51 0.44 0.27 0.65 0.31 0.14 0.37 0.15 0.01 0.01 0.03 0.01
30.28 29.30 28.74 27.29 27.63 27.79 27.55 27.78 27.91 27.91 27.89 27.92

Documents